DK2007362T3 - Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer - Google Patents
Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer Download PDFInfo
- Publication number
- DK2007362T3 DK2007362T3 DK07760105.2T DK07760105T DK2007362T3 DK 2007362 T3 DK2007362 T3 DK 2007362T3 DK 07760105 T DK07760105 T DK 07760105T DK 2007362 T3 DK2007362 T3 DK 2007362T3
- Authority
- DK
- Denmark
- Prior art keywords
- dosage form
- oral dosage
- clopidogrel
- omeprazole
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Anvendelse af en adenosindiphosphat (ADP)-antagonist eller P2Yi2-anta-gonist og en protonpumpehæmmer (PPI) til fremstilling af en farmaceutisk sammensætning til behandling af en patient med en gastrointestinal (GI) sygdom forbundet med en ADP- eller P2Yi2-antagonist hos en patient, hvor patienten ikke vides at have en GI sygdom, hvor den farmaceutiske sammensætning er en oral enkeltenhedsdoseringsform, der omfatter: (a) en terapeutisk virksom mængde af en adenosindiphosphat (ADP)-antago-nist eller P2Yi2-antagonist til hæmning af trombocytaggregation, hvor ADP- eller P2Yi2-antagonisten er clopidogrel eller et farmaceutisk acceptabelt salt, solvat, hydrat, enantiomer eller polymorf deraf; og (b) en terapeutisk virksom mængde af en PPI til forebyggelse af en GI sygdom forbundet med ADP- eller P2Yi2-antagonisten, hvor PPI'en er omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf; hvor PPI'en er enterisk coatet; og hvor den orale enkeltenhedsdoseringsform ikke indbefatter et ikke-aspirin ikke-steroidt anti-inflammatorisk lægemiddel (NSAID).
2. Anvendelse ifølge krav 1, hvor enhedsdoseringsformen omfatter ca. 20-200 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
3. Anvendelse ifølge krav 1 eller 2, hvor enhedsdoseringsformen omfatter ca. 10-100 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor enhedsdoseringsformen omfatter: (a) 50-100 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf; og/eller (b) 10-40 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
5. Anvendelse ifølge krav 1, hvor enhedsdoseringsformen omfatter ca. 75 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
6. Anvendelse ifølge krav 1,2,4 eller 5, hvor enhedsdoseringsformen omfatter ca. 20 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
7. Oral enkeltenhedsdoseringsform, der omfatter en terapeutisk virksom mængde af en adenosindiphosphat (ADP)-antagonist eller P2Yi2-antagonist og en terapeutisk virksom mængde af en protonpumpehæmmer (PPI), hvor ADP- eller P2Yi2-antagonisten er clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf, og PPI'en er omeprazol eller et farmaceutisk acceptabelt salt, ester, solvat, polymorf, hydrat eller enantiomer deraf, hvor PPI'en er enterisk coatet; og hvor doseringsformen er uden et ikke-steroidt anti-inflammatorisk lægemiddel (NSAID).
8. Doseringsform ifølge krav 7, hvor enhedsdoseringsformen omfatter ca. 20-200 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
9. Doseringsform ifølge 7 eller 8, hvor enhedsdoseringsformen omfatter ca. 10-100 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
10. Doseringsform ifølge et hvilket som helst af kravene 7 til 9, hvor enhedsdoseringsformen omfatter: (a) 50-100 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf; og/eller (b) 10-40 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
11. Doseringsform ifølge krav 7, hvor enhedsdoseringsformen omfatter ca. 75 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
12. Doseringsform ifølge krav 7, 8, 10 eller 11, hvor enhedsdoseringsformen omfatter ca. 20 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78954306P | 2006-04-04 | 2006-04-04 | |
US81232606P | 2006-06-09 | 2006-06-09 | |
PCT/US2007/065967 WO2007115305A2 (en) | 2006-04-04 | 2007-04-04 | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2007362T3 true DK2007362T3 (da) | 2018-11-26 |
Family
ID=38564311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07760105.2T DK2007362T3 (da) | 2006-04-04 | 2007-04-04 | Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer |
Country Status (24)
Country | Link |
---|---|
US (1) | US9504678B2 (da) |
EP (1) | EP2007362B1 (da) |
JP (3) | JP5844028B2 (da) |
KR (2) | KR20150105419A (da) |
CN (1) | CN101460154B (da) |
AU (1) | AU2007234398B9 (da) |
BR (1) | BRPI0709745A2 (da) |
CA (1) | CA2647497C (da) |
CY (1) | CY1120961T1 (da) |
DK (1) | DK2007362T3 (da) |
ES (1) | ES2699444T3 (da) |
HK (1) | HK1131566A1 (da) |
HR (1) | HRP20181971T1 (da) |
HU (1) | HUE040311T2 (da) |
IL (1) | IL194472A (da) |
LT (1) | LT2007362T (da) |
MX (2) | MX349787B (da) |
PL (1) | PL2007362T3 (da) |
PT (1) | PT2007362T (da) |
RS (1) | RS58162B1 (da) |
SG (1) | SG170826A1 (da) |
SI (1) | SI2007362T1 (da) |
TR (1) | TR201816133T4 (da) |
WO (1) | WO2007115305A2 (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007214474B2 (en) * | 2006-02-17 | 2011-01-20 | Novartis Ag | Disintegrable oral films |
MX349787B (es) | 2006-04-04 | 2017-08-11 | Kg Acquisition Llc | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. |
US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
HU230261B1 (hu) * | 2007-11-27 | 2015-11-30 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás gyógyszeripari intermedierek előállítására |
WO2009118763A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
CN101554378B (zh) * | 2008-04-09 | 2011-01-12 | 鲁南制药集团股份有限公司 | 含有普拉格雷的药物组合物 |
FR2932387B1 (fr) * | 2008-06-16 | 2010-09-17 | Cll Pharma | Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base. |
EP2303233B1 (en) * | 2008-07-25 | 2012-06-20 | Pharmathen S.A. | Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
WO2010041276A1 (en) * | 2008-10-06 | 2010-04-15 | Jubilant Organosys Limited | Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof |
CZ2008748A3 (cs) * | 2008-11-26 | 2010-06-02 | Zentiva, A. S | Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c] pyridin-2-yl acetátu, prasugrelu |
US20120141586A1 (en) * | 2009-06-08 | 2012-06-07 | Rubi Burlage | Thrombin receptor antagonist and clopidogrel fixed dose tablet |
CN101695496A (zh) * | 2009-10-15 | 2010-04-21 | 苏春华 | 一种含有三氟柳和氯吡格雷的药物组合物 |
JP2013032289A (ja) * | 2009-10-28 | 2013-02-14 | Daiichi Sankyo Co Ltd | ワックス安定製剤 |
HU229031B1 (en) | 2009-12-21 | 2013-07-29 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Process for producing prasurgel and its intermediate |
HU229035B1 (en) | 2009-12-21 | 2013-07-29 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Process for producing prasurgel |
EP2275087B8 (en) * | 2010-02-22 | 2012-11-21 | Jrs Pharma GmbH+Co.kG | Prasugrel controlled release formulations |
CN102232949A (zh) * | 2010-04-27 | 2011-11-09 | 孙远 | 提高药物溶出度的组合物及其制备方法 |
JP2012008044A (ja) * | 2010-06-25 | 2012-01-12 | Yamaguchi Univ | 血小板活性化能の測定方法および抗血小板薬の評価方法 |
HUP1000565A2 (en) | 2010-10-22 | 2012-05-02 | Egis Gyogyszergyar Nyrt | Process for the preparation of pharmaceutically active compound and intermediers |
CA2816957A1 (en) * | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
EP2734198A4 (en) * | 2011-06-24 | 2015-04-15 | Acenda Pharma Inc | METHOD AND IMPROVED PHARMACEUTICAL COMPOSITION FOR IMPROVING THE ABSORPTION OF AN ESTER PRODRUG |
CA2848756A1 (en) * | 2011-09-14 | 2013-03-21 | Pozen Inc. | Phased dosing of clopidogrel |
US20150079169A1 (en) * | 2011-09-14 | 2015-03-19 | Pozen Inc. | Controlled dosing of clopidogrel with gastric acid inhibition therapies |
CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
CN106860398A (zh) * | 2015-12-13 | 2017-06-20 | 北京蓝丹医药科技有限公司 | 一种高生物利用度的氯吡格雷药物组合物 |
HU231079B1 (hu) | 2016-06-23 | 2020-06-29 | Richter Gedeon Nyrt. | Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával |
KR20200024413A (ko) * | 2018-08-28 | 2020-03-09 | 에이치케이이노엔 주식회사 | 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물 |
UY39094A (es) | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
EP3939585A4 (en) * | 2020-05-20 | 2022-03-02 | Syntekabio, Inc. | PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 |
KR20240050841A (ko) * | 2022-10-12 | 2024-04-19 | 일양약품주식회사 | 클로피도그렐 및 일라프라졸을 포함하는 복합제제 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
US4464372A (en) | 1982-08-16 | 1984-08-07 | Schering Corporation | Imidazo[1,2-b]pyridazines |
US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US4833149A (en) | 1986-09-22 | 1989-05-23 | Ortho Pharmaceutical Corporation | 2- or 3-aryl substituted imidazo[1,2-a]pyridines |
FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
JPH0645536B2 (ja) | 1989-01-31 | 1994-06-15 | 日東電工株式会社 | 口腔粘膜貼付剤および口腔粘膜貼付製剤 |
US5041442A (en) | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
US5635477A (en) * | 1991-09-30 | 1997-06-03 | The Dupont Merck Pharmaceutical Company | Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA |
CN1134163A (zh) | 1993-08-19 | 1996-10-23 | 辛勒斯治疗系统公司 | 水溶性压敏粘膜粘合剂和配备该粘合剂用于放置在有粘膜衬里的体腔内的器具 |
KR100353384B1 (ko) | 1993-10-12 | 2002-12-28 | 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 | 장용성과립함유정제 |
US5576328A (en) * | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
EP1078628B1 (en) | 1994-07-08 | 2008-11-19 | AstraZeneca AB | Multiple unit tableted dosage form |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
AU3343295A (en) | 1994-08-12 | 1996-03-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Imidazopyridine salt |
DE69530989T2 (de) | 1994-08-13 | 2004-05-19 | Yuhan Corp. | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
SE9500478D0 (sv) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US6132768A (en) | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
US6252076B1 (en) | 1996-05-04 | 2001-06-26 | Yuhan Corporation | Process for preparation of pyrimidine derivatives |
EP0900214B1 (en) | 1996-05-04 | 2001-09-26 | Yuhan Corporation | Process for preparation of pyrimidine derivatives |
FR2751540B1 (fr) * | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
TR199900943T2 (xx) | 1996-10-29 | 1999-12-21 | Yuhan Corporation | Pirimidin t�revlerinin haz�rlanma prosesi. |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
PL337223A1 (en) * | 1997-06-05 | 2000-08-14 | Lilly Co Eli | Method of treating thrombotic disorders |
ZA987800B (en) | 1997-08-27 | 1999-06-09 | Hexal Ag | Pharmaceutical composition of meloxicam |
EA002806B1 (ru) | 1997-09-11 | 2002-10-31 | Нюкомед Данмарк А/С | Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid) |
US6296876B1 (en) | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
FR2774288B1 (fr) | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
US6184220B1 (en) | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
CA2241342C (en) | 1998-06-15 | 2000-02-08 | Bernard Charles Sherman | Pharmaceutical tablets comprising an nsaid and a prostaglandin |
US6365182B1 (en) | 1998-08-12 | 2002-04-02 | Cima Labs Inc. | Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet |
US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
FR2784583B1 (fr) | 1998-10-16 | 2002-01-25 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6761895B2 (en) * | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
PT1728794E (pt) | 2000-07-06 | 2008-07-15 | Ube Industries | Sal de adição maleato de derivados de hidropiridina |
US7008640B2 (en) | 2000-07-17 | 2006-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral use with improved absorption |
US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
US6670344B2 (en) | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
US20020131990A1 (en) | 2000-11-30 | 2002-09-19 | Barkalow David G. | Pullulan free edible film compositions and methods of making the same |
US6692771B2 (en) | 2001-02-23 | 2004-02-17 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
EP2260837A1 (en) | 2001-06-01 | 2010-12-15 | Pozen, Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US6656493B2 (en) | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
US6419903B1 (en) | 2001-08-20 | 2002-07-16 | Colgate Palmolive Company | Breath freshening film |
US6930099B2 (en) * | 2001-09-07 | 2005-08-16 | Advanced Medical Instruments | Composition for the treatment and prevention of endothelial dysfunction |
US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
US20040247649A1 (en) | 2002-02-11 | 2004-12-09 | Edizone, Lc | Medicine-containing orally soluble films |
US7014862B2 (en) | 2002-05-20 | 2006-03-21 | The Procter & Gamble Company | Chewable compositions containing a gel-forming extract of psyllium |
US6599539B1 (en) | 2002-07-31 | 2003-07-29 | Poulenger Usa Inc. | Perilla seed pesticide |
US6824829B2 (en) | 2002-08-23 | 2004-11-30 | Acupac Packaging, Inc. | Process for manufacturing thin film strips |
WO2004031143A2 (en) * | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
AU2003297752A1 (en) | 2002-12-06 | 2004-06-30 | Monosolrx Llc | Thin film delivery systems for volatile decongestants |
US20040151756A1 (en) | 2003-02-04 | 2004-08-05 | Richards Anthony P. | Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle |
US20050075432A1 (en) | 2003-10-07 | 2005-04-07 | Verrall Andrew P. | Acidulent film and method of making same |
EP1718303A4 (en) * | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
US20050196355A1 (en) | 2004-03-03 | 2005-09-08 | Constantine Georgiades | Film products having controlled disintegration properties |
US20060177504A1 (en) * | 2005-02-08 | 2006-08-10 | Renjit Sundharadas | Combination pain medication |
MX349787B (es) | 2006-04-04 | 2017-08-11 | Kg Acquisition Llc | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. |
US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
-
2007
- 2007-04-04 MX MX2013008976A patent/MX349787B/es unknown
- 2007-04-04 RS RS20181412A patent/RS58162B1/sr unknown
- 2007-04-04 CN CN200780020828.1A patent/CN101460154B/zh active Active
- 2007-04-04 AU AU2007234398A patent/AU2007234398B9/en active Active
- 2007-04-04 US US11/696,554 patent/US9504678B2/en active Active
- 2007-04-04 MX MX2008012514A patent/MX2008012514A/es not_active Application Discontinuation
- 2007-04-04 KR KR1020157021344A patent/KR20150105419A/ko not_active Application Discontinuation
- 2007-04-04 WO PCT/US2007/065967 patent/WO2007115305A2/en active Application Filing
- 2007-04-04 SG SG201102378-5A patent/SG170826A1/en unknown
- 2007-04-04 TR TR2018/16133T patent/TR201816133T4/tr unknown
- 2007-04-04 JP JP2009504449A patent/JP5844028B2/ja active Active
- 2007-04-04 CA CA2647497A patent/CA2647497C/en active Active
- 2007-04-04 BR BRPI0709745-0A patent/BRPI0709745A2/pt not_active Application Discontinuation
- 2007-04-04 PL PL07760105T patent/PL2007362T3/pl unknown
- 2007-04-04 ES ES07760105T patent/ES2699444T3/es active Active
- 2007-04-04 KR KR1020087026891A patent/KR101784001B1/ko active IP Right Grant
- 2007-04-04 EP EP07760105.2A patent/EP2007362B1/en active Active
- 2007-04-04 LT LTEP07760105.2T patent/LT2007362T/lt unknown
- 2007-04-04 SI SI200732067T patent/SI2007362T1/sl unknown
- 2007-04-04 HU HUE07760105A patent/HUE040311T2/hu unknown
- 2007-04-04 PT PT07760105T patent/PT2007362T/pt unknown
- 2007-04-04 DK DK07760105.2T patent/DK2007362T3/da active
-
2008
- 2008-10-02 IL IL194472A patent/IL194472A/en active IP Right Grant
-
2009
- 2009-12-11 HK HK09111673.2A patent/HK1131566A1/xx unknown
-
2013
- 2013-08-22 JP JP2013172493A patent/JP2013256525A/ja active Pending
-
2015
- 2015-10-01 JP JP2015195643A patent/JP2016028098A/ja active Pending
-
2018
- 2018-11-23 HR HRP20181971TT patent/HRP20181971T1/hr unknown
- 2018-12-05 CY CY181101302T patent/CY1120961T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2007362T3 (da) | Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer | |
US9532945B2 (en) | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor | |
US9636306B2 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
ES2208775T3 (es) | Formas de dosificacion efervescentes de multiples unidades que comprenden inhibidor de la bomba de protones. | |
US20070154542A1 (en) | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors | |
US20120128764A1 (en) | Controlled-release compositions comprising a proton pump inhibitor | |
NO316863B1 (no) | Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning | |
CA2592542A1 (en) | Dosage form for treating gastrointestinal disorders | |
KR20110104124A (ko) | 판토프라졸을 활성 성분으로서 함유하는 제형 | |
US20090214599A1 (en) | Proton pump inhibitor formulations, and methods of preparing and using such formulations | |
CA2740974A1 (en) | Dosage forms for the rapid and sustained elevation of gastric ph | |
US20110293713A1 (en) | Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs | |
CA2871221A1 (en) | Delayed release pharmaceutical compositions of salsalate |